Our Commitment to Patients and Partners
At Alnylam, we all live by a shared philosophy when it comes to patient access: our innovative therapies must get to those who need them. That philosophy of putting the patient first isn’t just a common belief among our leadership and employees, it’s a statement of intent and a specific set of actions that we’ve undertaken as a company. As part of our commitment, we publish an annual Patient Access Philosophy Report as a read-out on our progress.
Our Patient Access Philosophy was created well before our first medicine was even approved, because we wanted to ensure that in preparing to be a commercial-stage biopharmaceutical company, we had a North Star guiding how we behave and the decisions we make to ensure that patients around the world can access every medicine we develop. These principles guide our P5x25 strategy as we endeavor to become a top five biotech in the next five years.
At Alnylam, we know that medical and scientific innovation are only worthwhile if the people who can benefit from life-changing therapies have access to them. Despite living in an age of medicinal breakthroughs, patients are too often unable to receive the treatment they need due to their location, their insurance, or other obstacles. We are committed to working with partners around the world to ensure our drugs are accessible and affordable to all, because no patient should have to wait for hope. – John Maraganore, Ph.D., Founding CEO of Alnylam